Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

36.89
Delayed Data
As of Jul 29
 +0.22 / +0.60%
Today’s Change
28.25
Today|||52-Week Range
37.19
+14.28%
Year-to-Date
PFE Regular Dividend: PFE will begin trading ex-dividend on 08/03/16 with a $0.30 dividend payable to shareholders of record as of 08/05/16.
Jim Cramer's 'Mad Money' Recap: Here's What I'm Watching Next Week
Jul 29 / TheStreet.com - Paid Partner Content
3 Great Stocks For Retirees
Jul 29 / MotleyFool.com - Paid Partner Content
Trade-Ideas: Pfizer (PFE) Is Today's Post-Market Leader Stock
Jul 29 / TheStreet.com - Paid Partner Content
Better Buy: Regeneron Pharmaceuticals vs. Pfizer
Jul 29 / MotleyFool.com - Paid Partner Content
Tech Lights the Way on Strong Earnings
Jul 29 / TheStreet.com - Paid Partner Content
Sanofi Quarterly Earnings, Sales Slide, Reiterates Discipline on Medivation
Jul 29 / TheStreet.com - Paid Partner Content
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Jul 29 / Zacks.com - Paid Partner Content
Pfizer (PFE) Stock Down, Partners with Western Oncolytics on Cancer Technology
Jul 28 / TheStreet.com - Paid Partner Content
Buy Merck on Near-Term Weakness
Jul 29 / TheStreet.com - Paid Partner Content
3 Stocks Pushing The Health Care Sector Downward
Jul 28 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close36.67
Today’s open36.68
Day’s range36.65 - 36.95
Volume21,513,828
Average volume (3 months)32,882,113
Market cap$222.4B
Dividend yield3.25%
Data as of 4:00pm ET, 07/29/2016

Growth & Valuation

Earnings growth (last year)-21.24%
Earnings growth (this year)+11.39%
Earnings growth (next 5 years)+6.80%
Revenue growth (last year)-1.52%
P/E ratio30.2
Price/Sales4.13
Price/Book3.50

Competitors

 Today’s
change
Today’s
% change
NVSNovartis+1.18+1.44%
AGNPRAAllergan plc-3.53-0.39%
MRKMerck+0.23+0.39%
BMYBristol-Myers Squibb+0.15+0.20%
Data as of 4:02pm ET, 07/29/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)$0.61
Annual revenue (last year)$48.9B
Annual profit (last year)$7.0B
Net profit margin14.22%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman &
Chief Executive Officer
Ian C. Read
Chief Financial Officer &
EVP-Business Operations
Frank A. D'Amelio
Corporate headquarters
New York, New York

Forecasts

Partner Offers

Search for Jobs